Elisabeth Groß

6PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 14, 2023
Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells.

Sebastian W Schleser, Oleksandr Krytovych, Tim Ziegelmeier

|Jun 10, 2023
SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters.

Elisabeth Groß, Ralf-Axel Hilger, Franziska Lea Schümann

|Dec 24, 2021
Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas.

Franziska Lea Schümann, Elisabeth Groß, Marcus Bauer

|Oct 13, 2021
RBMX Protein Expression in T-Cell Lymphomas Predicts Chemotherapy Response and Prognosis.

Franziska Lea Schümann, Marcus Bauer, Elisabeth Groß

|Jun 02, 2021
BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.

Kathleen Gebhardt, Bayram Edemir, Elisabeth Groß

Pageof 1

Frequent Collaborators

5 joint publications

Thomas Weber

3 joint publications

Marcus Bauer

2 joint publications

Andreas Wienke

2 joint publications

Thomas Mueller